Adimmune Corporation (TPE:4142)

Adimmune Statistics

Total Valuation

Adimmune has a market cap or net worth of TWD 8.35 billion. The enterprise value is 9.96 billion.

Market Cap	8.35B
Enterprise Value	9.96B

Important Dates

The next estimated earnings date is Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Adimmune has 421.51 million shares outstanding.

Current Share Class	421.51M
Shares Outstanding	421.51M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	1.41%
Owned by Institutions (%)	3.05%
Float	316.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.95
PB Ratio	1.72
P/TBV Ratio	1.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-19.58
EV / Sales	8.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-19.55

Financial Position

The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.67.

Current Ratio	1.85
Quick Ratio	1.24
Debt / Equity	0.67
Debt / EBITDA	n/a
Debt / FCF	-6.43
Interest Coverage	-21.32

Financial Efficiency

Return on equity (ROE) is -11.45% and return on invested capital (ROIC) is -4.67%.

Return on Equity (ROE)	-11.45%
Return on Assets (ROA)	-4.50%
Return on Invested Capital (ROIC)	-4.67%
Return on Capital Employed (ROCE)	-9.34%
Revenue Per Employee	2.13M
Profits Per Employee	-901,773
Employee Count	564
Asset Turnover	0.14
Inventory Turnover	1.23

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.00% in the last 52 weeks. The beta is 0.45, so Adimmune's price volatility has been lower than the market average.

Beta (5Y)	0.45
52-Week Price Change	-10.00%
50-Day Moving Average	19.65
200-Day Moving Average	18.41
Relative Strength Index (RSI)	50.32
Average Volume (20 Days)	2,001,777

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Adimmune had revenue of TWD 1.20 billion and -508.60 million in losses. Loss per share was -1.21.

Revenue	1.20B
Gross Profit	32.12M
Operating Income	-612.14M
Pretax Income	-601.10M
Net Income	-508.60M
EBITDA	-436.17M
EBIT	-612.14M
Loss Per Share	-1.21

Balance Sheet

The company has 1.79 billion in cash and 3.27 billion in debt, with a net cash position of -1.49 billion or -3.52 per share.

Cash & Cash Equivalents	1.79B
Total Debt	3.27B
Net Cash	-1.49B
Net Cash Per Share	-3.52
Equity (Book Value)	4.85B
Book Value Per Share	11.21
Working Capital	1.55B

Cash Flow

In the last 12 months, operating cash flow was -174.08 million and capital expenditures -335.28 million, giving a free cash flow of -509.36 million.

Operating Cash Flow	-174.08M
Capital Expenditures	-335.28M
Free Cash Flow	-509.36M
FCF Per Share	-1.21

Margins

Gross margin is 2.67%, with operating and profit margins of -50.96% and -42.34%.

Gross Margin	2.67%
Operating Margin	-50.96%
Pretax Margin	-50.05%
Profit Margin	-42.34%
EBITDA Margin	-36.31%
EBIT Margin	-50.96%
FCF Margin	n/a

Dividends & Yields

Adimmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-6.09%
FCF Yield	-6.10%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Adimmune has an Altman Z-Score of 1.56 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.56
Piotroski F-Score	2